Last reviewed · How we verify

Polyethylene Glycol Recombinant Human Somatropin

Shandong University · Phase 1 active Small molecule Quality 0/100

Polyethylene Glycol Recombinant Human Somatropin is a Small molecule drug developed by Shandong University. It is currently in Phase 1 development.

At a glance

Generic namePolyethylene Glycol Recombinant Human Somatropin
SponsorShandong University
ModalitySmall molecule
PhasePhase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Polyethylene Glycol Recombinant Human Somatropin

What is Polyethylene Glycol Recombinant Human Somatropin?

Polyethylene Glycol Recombinant Human Somatropin is a Small molecule drug developed by Shandong University.

Who makes Polyethylene Glycol Recombinant Human Somatropin?

Polyethylene Glycol Recombinant Human Somatropin is developed by Shandong University (see full Shandong University pipeline at /company/shandong-university).

What development phase is Polyethylene Glycol Recombinant Human Somatropin in?

Polyethylene Glycol Recombinant Human Somatropin is in Phase 1.

Related